Finance

Beta
Lists
CGON:NASDAQ
CG Oncology Inc
$71.96
-1.21%
(-0.88) 1D
$71.96
-0.00% (-0.0013)
After hours
Closed: Jun 26, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGON...
Open
$72.79
High
$74.74
Low
$69.51
Mkt. cap
6.35B
Avg. vol.
1.03M
Volume
4.85M
52-wk high
$75.50
52-wk low
$23.65
EPS
-$2.34
Shares outstanding
88.20M
No. of employees
142
Open
$72.79
High
$74.74
Low
$69.51
Mkt. cap
6.35B
Avg. vol.
1.03M
Volume
4.85M
52-wk high
$75.50
52-wk low
$23.65
EPS
-$2.34
Shares outstanding
88.20M
No. of employees
142
News stories
From sources across the web
About CG Oncology Inc
CEO-
Employees142
Founded2010
HeadquartersIrvine, California, United States
SectorBiotechnology
Websitecgoncology.com
Analyst ratings
Based on 14 analysts giving stock ratings to CGON in the past 3 months
Strong buy
Buy
13
Hold
1
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for CGON in the last 3 months.
Highest
Current $71.96
$108.00 (+50.08%)
Average
$91.55 (+27.22%)
Lowest
$80.00 (+11.17%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$82.00
+14%
06/23/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$85.00
+18.1%
06/16/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
05/27/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$87.00
+20.9%
05/26/2026
Kalpit Patel
Wolfe Research
Hold
Maintained
-
-
05/26/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$80.00
+11.2%
05/18/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$100.00
+39%
05/18/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$108.00
+50.1%
05/16/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$93.00
+29.2%
05/15/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$96.00
+33.4%
05/11/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$105.00
+45.9%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
David Dai
UBS
Buy
Maintained
$90.00
+25.1%
05/08/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$81.00
+12.6%
05/08/2026
Soumit Roy
JonesTrading
Buy
Maintained
$85.00
+18.1%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$90.00
+25.1%
02/27/2026
Last report
May 8, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.71 / -$0.54
-31.53%miss
Revenue / Est. (USD)
1.08M / 453.03K
+139.06%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
1.67M
2.32M
1.08M
Cost of goods sold
31.33M
29.46M
33.03M
46.69M
Cost of revenue
31.33M
29.46M
33.03M
46.69M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.41M
23.33M
17.99M
20.78M
Operating expense
17.41M
23.33M
17.99M
20.78M
Total operating expenses
48.74M
52.80M
51.02M
67.47M
Operating income
-48.74M
-51.13M
-48.70M
-66.39M
Other non operating income
-4.00K
-100.00K
-53.00K
-101.00K
EBT including unusual items
-41.43M
-43.81M
-41.31M
-60.20M
EBT excluding unusual items
-41.43M
-43.81M
-41.31M
-60.20M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-41.43M
-43.81M
-41.31M
-60.20M
Net profit margin
-
-2,629.53%
-1,779.03%
-5,558.82%
Earnings per share
-0.54
-0.57
-0.51
-0.71
Interest and investment income
7.32M
7.42M
7.44M
6.29M
Interest expense
-
-
-
-
Net interest expenses
7.32M
7.42M
7.44M
6.29M
Depreciation and amortization charges
-
-
-
-
EBITDA
-48.58M
-50.71M
-47.85M
-65.55M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of CGON
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer